AeroRx Therapeutics Inc
AeroRx Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary nebulized combination therapies for chronic respiratory diseases. Their lead product candidate, AERO-007, is the first potential nebulized LABA/LAMA fixed-dose combination drug in clinical development as a first-line maintenance therapy for chronic obstructive pulmonary disease (COPD). AeroRx aims to address the unmet needs of patients who are inadequately served by existing inhaler-based therapies. The company is also developing AERO-111, a potential nebulized LABA/LAMA/ICS triple therapy for patients requiring escalation beyond dual bronchodilators. AeroRx is based in La Jolla, California.
Leadership & Board
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $21M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $21M
- Latest Funding Round
- Series A
- Post-Money Valuation
- ―
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 08, 2025 | Series A | $21.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Alexandria Venture Investments | Series A |
| Correlation Ventures | Series A |
| Avalon BioVentures | Series A |
Similar Companies
A snapshot of private companies similar to AeroRx Therapeutics Inc, helping you discover and navigate related company profiles.
Related News and Analysis
